Name: 글로벌 자동 유방 초음파 시스템(ABUS) 시장 - 2023-2030 - Prime research
SKU: DMMD914
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 자동 유방 초음파 시스템 시장 규모는 2023년 1,424만 달러였으며, 2030년까지 24억 5,200만 달러에 이를 것으로 예상됩니다. 예측 기간(2023~2030년) 동안 연평균 성장률(CAGR)은 12.4%입니다.
자동 유방 초음파(ABUS)는 유방 조직이 치밀한 여성(지방보다 선 조직이나 섬유 조직이 많은 여성)에서 종양을 최대 30% 더 많이 발견할 수 있습니다. 유방 조직이 치밀한 여성은 유방 조영술만으로는 충분한 진단을 받기 어려울 수 있지만, ABUS를 통해 더 많은 악성 종양을 발견할 수 있습니다. 초음파 검사에는 방사선이 사용되지 않으며, ABUS는 치밀한 유방을 촬영하는 빠르고 통증 없는 효율적인 방법입니다.

시장 동향
전 세계 자동 유방 초음파 시스템 시장을 이끄는 주요 요인은 전 세계적으로 증가하는 유방암 발병률입니다. 자동 유방 초음파 시스템의 기술 발전과 유방암에 대한 인식 제고, 그리고 정부의 우호적인 정책들이 시장 성장을 견인하고 있습니다.
전 세계적인 유방암 발병률 증가는 시장의 가장 중요한 성장 동력입니다.
세계보건기구(WHO)에 따르면, 유방암은 유방의 선 조직에서 유관(85%) 또는 소엽(15%)의 살아있는 세포(상피)에서 시작됩니다. 악성 종양은 초기에는 유관이나 소엽에 국한되어 증상이 나타나지 않는 경우가 많고 전이 위험도 낮습니다. 2020년 전 세계적으로 68만 4천 명이 유방암으로 사망했으며, 이 중 230만 명이 여성이었습니다. 2020년 말 기준 전 세계에서 가장 흔한 암은 유방암으로, 지난 5년간 780만 명의 여성이 진단받았습니다. 유방암은 전 세계 여성에게 가장 많은 장애보정수명손실(DALY)을 초래하는 암입니다. 유방암은 사춘기 이후 모든 연령대의 여성에게 발생하지만, 특히 노년층에서 발생률이 증가합니다.
미국 암 협회는 2022년에 여성에서 침습성 유방암 신규 환자가 약 287,840명, 관상피내암(DCIS) 신규 환자가 약 51,400명, 유방암 관련 사망자가 약 43,250명에 이를 것으로 예측했습니다. 유방암은 중년 이상의 여성에게 더 흔하며, 유방암 진단 평균 연령은 62세입니다. 따라서 여성 유방암 발견 평균 연령은 62세 이하입니다. 45세 미만 여성의 유방암 진단은 매우 드뭅니다.
자동 유방 초음파 시스템의 높은 가격은 시장 성장을 저해할 것입니다.

자동 유방 초음파 영상 시스템의 적용은 여러 국가에서 엄격한 규제로 인해 제한되어 왔습니다. 또한, 기존 암 검진 방법에 비해 자동 유방 초음파 시스템(ABUS)의 높은 비용이 시장 확장을 저해할 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19 팬데믹이 시작되면서 감염병의 발생 빈도와 심각성 및 확산 속도가 증가했습니다. 전 세계적인 팬데믹 초기에는 COVID-19 바이러스 감염 환자 수가 급증했습니다. 다양한 감염병의 전파를 줄이고 통제하기 위해 병원들은 최우선적으로 응급 프로토콜을 채택했습니다. 이로 인해 초음파 검사가 필요한 선택적 시술이 감소했습니다. 선택적 초음파 치료가 감소했음에도 불구하고 영상 서비스가 필요한 응급 시술에 X선, CT 스캔 및 초음파 사용이 증가했습니다. COVID-19의 장기적인 영향으로 인해 신장 및 폐와 같은 특수 진단을 위한 초음파 장비 도입이 증가할 것으로 예상됩니다. 폐 초음파 수술 건수는 팬데믹 초기에 증가 추세를 보였습니다.

부문 분석
병원 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
환자의 진단 수요를 충족하기 위해 더 많은 병원에서 ABUS(자동 유방 초음파 검사) 도입이 점차 확대되고 있습니다. 이러한 의료 환경에서 ABUS에 대한 수요는 젊은 여성과 중년 여성의 암 검진 이용 증가에 의해 주도될 것입니다. 임산부는 방사선 위험 때문에 유방촬영술을 받을 수 없으므로, 병원에서는 보다 안전한 진단 방법을 제공하기 위해 ABUS를 설치하고 있습니다.
유방암 수술은 종양을 제거하는 수술로, 질병 치료의 중요한 부분입니다. 유방암 수술은 단독으로 시행되거나 화학요법, 호르몬 요법, 표적 치료, 방사선 치료와 같은 다른 치료법과 병행하여 자격을 갖춘 의사의 지도 하에 병원에서 시행될 수 있습니다.
매년 10만 명 이상의 미국 여성이 유방 절제술을 받습니다. 유방 절제술은 유방암 치료를 위해 흔히 시행되지만, 유방암 발병 가능성을 낮추기 위해 시행되는 경우도 있습니다. 의사의 감독 하에 병원에서 시술이 이루어져야 하므로 병원 부문이 시장을 주도합니다. 여러 선진국의 교육 병원은 일반 병원이나 전문 병원에 비해 다양한 치료 방식에 대한 수요가 급격히 증가했습니다. 그러나 북미 개발도상국에서는 신규 병원 수가 급증하고 있습니다. 영상 진단 장비는 일반적으로 신설 병원에 도입될 여지가 많습니다. 경쟁 심화와 최고 수준의 의료 서비스에 대한 수요 증가는 이 부문의 성장을 견인할 것으로 예상되는 두 가지 주요 요인입니다.
지리적 분석
북미는 전 세계 자동 유방 초음파 시스템 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
미국 암 학회에 따르면 2021년 여성에게서 약 281,550건의 새로운 유방암 사례가 발견되고 43,600명의 여성이 이 질병으로 사망할 것으로 예상됩니다. 유방암 발병률이 증가함에 따라 최첨단 유방 영상 장비와 효율적인 치료 지원에 대한 필요성이 커지고 있습니다. 미국 정부의 유방암 정보 제공 및 검진의 중요성 교육 캠페인이 강화됨에 따라 미국 내 자동 유방 초음파 시스템(ABUS) 시장은 성장할 것으로 전망됩니다. 유방암협회(Breast Cancer Organization)에 따르면 미국 여성 8명 중 1명(약 13%)이 결국 침습성 유방암에 걸릴 것으로 예상됩니다.
미국에서는 2022년에 침습성 유방암 신규 환자가 287,840명, 비침습성(상피내) 유방암 신규 환자가 51,500명 발생할 것으로 예상됩니다. 같은 해 남성의 경우 침습성 유방암 신규 환자가 2,710명 발생할 것으로 예상되며, 남성 833명 중 1명꼴로 유방암에 걸릴 수 있습니다. 2022년 1월 기준 미국에서는 380만 명이 넘는 여성이 유방암 진단을 받았습니다. 여기에는 치료를 완료한 여성과 현재 치료를 받고 있는 여성이 모두 포함됩니다. 미국에서는 수잔 코멘 재단(Susan Komen Foundation), 전국 유방암 재단(National Breast Cancer Foundation), 미국 암 학회(American Society of Cancer)의 전국 유방암 인식의 달(NBCA) 등 여러 재단에서 유방암 인식 제고 프로그램을 진행하고 있습니다. 이는 세포 밀도가 높은 유방 조직에서 유방암을 탐지하기 위한 자동 유방 초음파 시스템에 대한 수요를 충족하는 데 도움이 될 것입니다.
경쟁 환경
자동 유방 초음파 시스템 시장은 GE Healthcare, Hitachi, Ltd, Koninklijke Philips N.V., Siemens AG, SonoCiné Inc, Qview Medical, Hologic Inc, Volpara Solutions Limited, Delphinus Medical Technologies, Inc., Nova Medical Inc 등 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 주요 업체들은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 채택하여 시장 성장에 기여하고 있습니다. 예를 들어, 초음파를 이용한 암 진단 분야의 선구자인 Koios Medical에 따르면, 인공지능(AI) 기반 소프트웨어 플랫폼인 Koios DS는 초음파 검사에서 갑상선암과 유방암을 효과적으로 진단하는 것으로 입증되어 2022년 12월 EU 의료기기 규정(MDR)에 따라 CE 마크를 획득했습니다. 전 세계 55개 지점의 데이터를 활용하여 개발된 혁신적인 이중 진단 방식은 판독 속도를 높이고, 보고를 자동화하며, 불필요한 수술을 없애는 동시에 약물 투여 시간을 단축합니다.
제너럴 일렉트릭 컴퍼니(GE)

개요: 제너럴 일렉트릭 컴퍼니(GE)의 사업부인 GE 헬스케어는 진단 영상 및 임상 시스템을 비롯하여 신약 개발, 바이오 의약품 생산 및 세포 기술을 위한 다양한 의료 IT 솔루션, 제품 및 서비스를 개발, 생산 및 판매하는 글로벌 의료기기 공급업체입니다. 또한 GE 헬스케어는 컴퓨터 데이터 관리, 자사 및 타사에서 제조한 의료 장비에 대한 원격 진단 및 수리 서비스, 성능 향상 및 성능 솔루션 서비스 등을 제공합니다.
제품 포트폴리오:
인베니아 아부스 2.0(Invenia ABUS 2.0): 유방암 발병의 가장 흔한 위험 요인 중 하나는 유방 비대증으로, 약 40%의 여성에게 영향을 미칩니다. 유방조영술로는 발견할 수 없는 미세하고 림프절 전이가 없는 침습성 종양을 초음파로 탐지하는 데 대한 임상 데이터가 점차 증가하고 있습니다. 유방 밀도가 높은 경우 선별 검사 시 영상 촬영을 위해 Invenia ABUS 2.0 보조 영상 촬영 시스템이 설계되었습니다.
글로벌 자동 유방 초음파 시스템 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림 및 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The global automated breast ultrasound systems market size was valued at US$ 14,24 million in 2023 and is estimated to reach US$ 2452 million by 2030, growing at a CAGR of 12.4% during the forecast period (2023-2030).
A more popular technique, Automated Breast Ultrasound (ABUS), can detect up to 30% more tumors in women with dense breast tissue (more glandular or fibrous than fatty), even if it is the only extra risk factor. Women with denser breasts may make mammography insufficient and can employ ABUS to discover more malignancies. No ionizing radiation is used during ultrasound procedures, and ABUS is a quick, painless, and efficient approach to photographing dense breasts.
Market Dynamics
The major factors driving the global Automated breast ultrasound systems market rising prevalence of breast cancer worldwide is the most significant driving factor of the market, as increasing technological advancements in automated breast ultrasound systems and rising awareness regarding breast cancer favorable government initiatives.
The rising prevalence of breast cancer worldwide is the most significant driving factor in the market.
According to WHO, in the glandular tissue of the breast, breast cancer begins in the living cells (epithelium) of the ducts (85%) or lobules (15%). The malignant development is initially restricted to the duct or lobule, where it often exhibits no symptoms and has a low risk of spreading. 684,000 people worldwide died in 2020 due to breast cancer, which affected 2.3 million women. The most common cancer globally as of the end of 2020 was breast cancer, diagnosed in 7.8 million women in the previous five years. Breast cancer is the form of cancer that results in the most lost disability-adjusted life years (DALYs) for women globally. Breast cancer occurs in every nation of the world in women at any age after puberty but with rising rates in later life.
The American Cancer Society predicts that in 2022, there will be about 287,840 new cases of invasive breast cancer in women, about 51,400 new instances of ductal carcinoma in situ (DCIS), and about 43,250 new cases of breast cancer-related deaths in women. Breast cancer is more common in women in their middle years and older. The typical age at breast cancer diagnosis is 62 years old. The average age at which breast cancer in women is found is therefore 62 years of age or less. Breast cancer diagnoses in women under 45 are incredibly uncommon.
The automated breast ultrasound system's high price will hamper the market’s growth.
The application of automated breast ultrasound imaging systems has been constrained by severe rules in a number of nations. Additionally, the high cost of automated breast ultrasound systems (ABUS) compared to traditional cancer screening methods is anticipated to restrain market expansion.
COVID-19 Impact Analysis
Infectious disease frequency increased in terms of the severity and rate of dissemination with the beginning of the COVID-19 pandemic. During the early stages of the global pandemic, the number of patients infected with the COVID-19 virus increased. To decrease and control different infection transmission, hospitals adopted emergency protocols as a top priority. This led to a decline in elective procedures that needed ultrasound screening. The use of X-rays, CT scans, and ultrasounds for emergency procedures that needed imaging services increased despite a reduction in elective ultrasound treatments. The adoption of ultrasound equipment for specialized diagnostics, notably for kidneys and lungs, is anticipated to increase due to COVID-19's long-term effects. The number of ultrasound operations for lungs exhibited a rising trend during the early stages of the pandemic.
Segment Analysis
The hospital’s segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
ABUS implementation is progressively gaining momentum in more hospitals to meet the patients' diagnostic demands. The demand for ABUS in these healthcare settings will be driven by rising cancer screening test usage among young and middle-aged women. Hospitals are installing ABUS to provide safer diagnostic choices because pregnant women cannot get mammography due to the radiation danger.
Breast cancer surgery involves operating to remove the tumor, which is a crucial part of treatment for the disease. Breast cancer surgery can be used either on its own or in conjunction with other therapies, such as chemotherapy, hormone therapy, targeted therapy, and radiation therapy, administered in a hospital setting under the guidance of a qualified doctor.
Each year, more than 100,000 American women get a mastectomy. Although it is frequently done to treat breast cancer, it is occasionally done to lower the chance of developing breast cancer. Because procedures must be performed in hospitals under the supervision of doctors, the hospital sector drives the market. Compared to general or specialty hospitals, teaching hospitals in several affluent nations have seen a dramatic increase in demand for various treatment modalities. However, the number of new hospitals in developing nations in North America has sharply increased. Imaging modalities typically have their room in new hospitals. Rising competition and rising demand for top-notch medical care are the two main reasons predicted to drive segment expansion.
Geographical Analysis
North America holds the largest market share in the global automated breast ultrasound systems market.
According to the American Society of Cancer, about 281,550 new breast cancer cases will be discovered in women in 2021, and 43,600 women will pass away from the disease. The prevalence of breast cancer is rising, increasing the need for cutting-edge breast imaging equipment and support for efficient therapies. The ABUS market in the U.S. will grow as government campaigns to inform and educate women about breast cancer and the value of screening increase. According to the Breast Cancer Organization, 1 in 8 (or around 13%) American women will eventually develop invasive breast cancer.
In the United States, women are anticipated to receive diagnoses for 287,840 new instances of invasive breast cancer and 51,500 new cases of non-invasive (in situ) breast cancer in 2022. In 2022, it's anticipated that 2,710 new instances of invasive breast cancer will be found in men. About 1 in 833 men may develop breast cancer in their lives. In the U.S., more than 3.8 million women have had breast cancer in the past as of January 2022. Women who have completed treatment and those who are presently receiving it are included. Several foundations in the United States have launched awareness programs, including the Susan Komen Foundation, the National Breast Cancer Foundation, and the American Society of Cancer's National Breast Cancer Awareness (NBCA) month. These will benefit the need for automated breast ultrasonography systems for detecting breast cancer in breast tissue with dense cellularity.
Competitive Landscape
The Automated breast ultrasound systems market is moderately competitive with local and global companies’ presence GE Healthcare, Hitachi, Ltd, Koninklijke Philips N.V., Siemens AG , SonoCiné Inc, Qview Medical, Hologic Inc, Volpara Solutions Limited, Delphinus Medical Technologies, Inc., Nova Medical Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in December 2022, Koios DS, a software platform powered by artificial intelligence (AI) and shown to effectively diagnose thyroid and breast malignancies in ultrasound tests, has received CE Marking under the EU MDR, according to Koios Medical, a pioneer in the field of cancer diagnostics using ultrasound. The innovative dual-diagnosis method, developed utilizing data from a global network of 55 sites, speeds up interpretation, automates reporting, and shortens the time it takes to administer medication while eliminating unnecessary surgery
General Electric Company.
Overview: E Healthcare, a division of General Electric Company, is a global provider of medical devices that creates, develops, produces, and sells diagnostic imaging and clinical systems, as well as a variety of healthcare IT solutions, products and services for drug discovery, biopharmaceutical production, and cellular technologies. Additionally, GE Healthcare offers services including computerized data management, remote diagnostic and repair services for medical equipment made by the business and others, performance enhancement and performance solutions services, and other services.
Product Portfolio:
Invenia ABUS 2.0: One of the biggest widespread risk factors for getting breast cancer is having thick breasts, which affects about 40% of women. The clinical data supporting the use of ultrasonography to detect tiny, node-negative, invasive tumors that mammography misses is emerging. For dense breast imaging in the screening context, Invenia ABUS 2.0 supplemental imaging is designed.
The global automated breast ultrasound systems market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing technological advancements in automated breast ultrasound systems
4.1.1.2. Rising awareness regarding breast cancer and favorable government initiatives
4.1.2. Restraints:
4.1.2.1. The automated breast ultrasound system's high price
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Ultrasound Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
7.1.2. Market Attractiveness Index, By Ultrasound Type
7.2. Doppler ultrasound
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Color Doppler
7.4. Transvaginal ultrasound
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Breast imaging
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Screening
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Imaging Centers
9.4. Diagnostic Laboratories
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. General Healthcare Company
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Hitachi, Ltd
12.3. Koninklijke Philips N.V.
12.4. Siemens AG
12.5. SonoCine Inc
12.6. Qview Medical
12.7. Koios Medical
12.8. Volpara Solutions Limited
12.9. Delphinus Medical Technologies, Inc.
12.10. Nova Medical Inc
LIST NOT EXHAUSTIVE
13. Global Automated breast ultrasound systems Market – DataM
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us

언급된 주요 기업들

General Healthcare Company, Hitachi, Ltd, Koninklijke Philips N.V., Siemens AG, SonoCine Inc, Qview Medical, Koios Medical, Volpara Solutions Limited, Delphinus Medical Technologies, Inc., Nova Medical Inc

표 목록 (Tables)

List of Tables

Table N0.1 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2023, 2027 & 2031 ($ Million)

Table N0.2 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table N0.3 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2023, 2027 & 2031 ($ Million)

Table N0.4 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table N0.5 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2023, 2027 & 2031 ($ Million)

Table N0.6 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2022-2031 ($ Million)

Table N0.7 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table N0.8 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2022-2031 ($ Million)

Table N0.9 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2023, 2027 & 2031 ($ Million)

Table N0.10 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2022-2031 ($ Million)

Table N0.11 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table N0.12 Global Automated Breast Ultrasound Systems (ABUS) Market Value, By Region, 2022-2031 ($ Million)

Table N0.13 North America Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2022-2031 ($ Million)

Table N0.14 North America Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2022-2031 ($ Million)

Table N0.15 North America Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2022-2031 ($ Million)

Table N0.16 North America Automated Breast Ultrasound Systems (ABUS) Market Value, By Country, 2022-2031 ($ Million)

Table N0.17 South America Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2022-2031 ($ Million)

Table N0.18 South America Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2022-2031 ($ Million)

Table N0.19 South America Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2022-2031 ($ Million)

Table N0.20 South America Automated Breast Ultrasound Systems (ABUS) Market Value, By Country, 2022-2031 ($ Million)

Table N0.21 Europe Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2022-2031 ($ Million)

Table N0.22 Europe Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2022-2031 ($ Million)

Table N0.23 Europe Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2022-2031 ($ Million)

Table N0.24 Europe Automated Breast Ultrasound Systems (ABUS) Market Value, By Country, 2022-2031 ($ Million)

Table N0.25 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2022-2031 ($ Million)

Table N0.26 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2022-2031 ($ Million)

Table N0.27 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2022-2031 ($ Million)

Table N0.28 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Value, By Country, 2022-2031 ($ Million)

Table N0.29 Middle East & Africa Automated Breast Ultrasound Systems (ABUS) Market Value, By Ultrasound Type, 2022-2031 ($ Million)

Table N0.30 Middle East & Africa Automated Breast Ultrasound Systems (ABUS) Market Value, By Application, 2022-2031 ($ Million)

Table N0.31 Middle East & Africa Automated Breast Ultrasound Systems (ABUS) Market Value, By End-User, 2022-2031 ($ Million)

Table N0.32 GE Healthcare: Overview

Table N0.33 GE Healthcare: Product Portfolio

Table N0.34 GE Healthcare: Key Developments

Table N0.35 Hitachi, Ltd: Overview

Table N0.36 Hitachi, Ltd: Product Portfolio

Table N0.37 Hitachi, Ltd: Key Developments

Table N0.38 Koninklijke Philips N.V.: Overview

Table N0.39 Koninklijke Philips N.V.: Product Portfolio

Table N0.40 Koninklijke Philips N.V.: Key Developments

Table N0.41 Siemens AG : Overview

Table N0.42 Siemens AG : Product Portfolio

Table N0.43 Siemens AG : Key Developments

Table N0.44 SonoCiné Inc: Overview

Table N0.45 SonoCiné Inc: Product Portfolio

Table N0.46 SonoCiné Inc: Key Developments

Table N0.47 Qview Medical : Overview

Table N0.48 Qview Medical : Product Portfolio

Table N0.49 Qview Medical : Key Developments

Table N0.50 Koios Medical : Overview

Table N0.51 Koios Medical : Product Portfolio

Table N0.52 Koios Medical : Key Developments

Table N0.53 Volpara Solutions Limited : Overview

Table N0.54 Volpara Solutions Limited : Product Portfolio

Table N0.55 Volpara Solutions Limited : Key Developments

Table N0.56 Delphinus Medical Technologies, Inc.: Overview

Table N0.57 Delphinus Medical Technologies, Inc.: Product Portfolio

Table N0.58 Delphinus Medical Technologies, Inc.: Key Developments

Table N0.59 Nova Medical Inc: Overview

Table N0.60 Nova Medical Inc: Product Portfolio

Table N0.61 Nova Medical Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure N0.1 Global Automated Breast Ultrasound Systems (ABUS) Market Share, By Ultrasound Type, 2022 & 2031 (%)

Figure N0.2 Global Automated Breast Ultrasound Systems (ABUS) Market Share, By Application, 2022 & 2031 (%)

Figure N0.3 Global Automated Breast Ultrasound Systems (ABUS) Market Share, By End-User, 2022 & 2031 (%)

Figure N0.4 Global Automated Breast Ultrasound Systems (ABUS) Market Share, By Region, 2022 & 2031 (%)

Figure N0.5 Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.6 Global Automated Breast Ultrasound Systems (ABUS) Market Y-o-Y Growth, By Ultrasound Type, 2022-2031 (%)

Figure N0.7 Doppler ultrasound: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.8 "Color Doppler: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)"

Figure N0.9 "Transvaginal ultrasound: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)"

Figure N0.10 Global Automated Breast Ultrasound Systems (ABUS) Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure N0.11 Breast imaging: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.12 "Screening: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)"

Figure N0.13 Global Automated Breast Ultrasound Systems (ABUS) Market Y-o-Y Growth, By End-User, 2022-2031(%)

Figure N0.14 Hospitals: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.15 "Diagnostic Imaging Centers

: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)"

Figure N0.16 "Diagnostic Laboratories

: Global Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)"

Figure N0.17 Global Automated Breast Ultrasound Systems (ABUS) Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure N0.18 North America Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.19 North America Automated Breast Ultrasound Systems (ABUS) Market Share, By Ultrasound Type, 2022 & 2031 (%)

Figure N0.20 North America Automated Breast Ultrasound Systems (ABUS) Market Share, By Application, 2022 & 2031 (%)

Figure N0.21 North America Automated Breast Ultrasound Systems (ABUS) Market Share, By End-User, 2022 & 2031 (%)

Figure N0.22 North America Automated Breast Ultrasound Systems (ABUS) Market Share, By Country, 2022 & 2031 (%)

Figure N0.23 South America Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.24 South America Automated Breast Ultrasound Systems (ABUS) Market Share, By Ultrasound Type, 2022 & 2031 (%)

Figure N0.25 South America Automated Breast Ultrasound Systems (ABUS) Market Share, By Application, 2022 & 2031 (%)

Figure N0.26 South America Automated Breast Ultrasound Systems (ABUS) Market Share, By End-User, 2022 & 2031 (%)

Figure N0.27 South America Automated Breast Ultrasound Systems (ABUS) Market Share, By Country, 2022 & 2031 (%)

Figure N0.28 Europe Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.29 Europe Automated Breast Ultrasound Systems (ABUS) Market Share, By Ultrasound Type, 2022 & 2031 (%)

Figure N0.30 Europe Automated Breast Ultrasound Systems (ABUS) Market Share, By Application, 2022 & 2031 (%)

Figure N0.31 Europe Automated Breast Ultrasound Systems (ABUS) Market Share, By End-User, 2022 & 2031 (%)

Figure N0.32 Europe Automated Breast Ultrasound Systems (ABUS) Market Share, By Country, 2022 & 2031 (%)

Figure N0.33 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.34 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Share, By Ultrasound Type, 2022 & 2031 (%)

Figure N0.35 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Share, By Application, 2022 & 2031 (%)

Figure N0.36 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Share, By End-User, 2022 & 2031 (%)

Figure N0.37 Asia-Pacific Automated Breast Ultrasound Systems (ABUS) Market Share, By Country, 2022 & 2031 (%)

Figure N0.38 Middle East & Africa Automated Breast Ultrasound Systems (ABUS) Market Value, 2022-2031 ($ Million)

Figure N0.39 Middle East & Africa Automated Breast Ultrasound Systems (ABUS) Market Share, By Ultrasound Type, 2022 & 2031 (%)

Figure N0.40 Middle East & Africa Automated Breast Ultrasound Systems (ABUS) Market Share, By Application, 2022 & 2031 (%)

Figure N0.41 Middle East & Africa Automated Breast Ultrasound Systems (ABUS) Market Share, By End-User, 2022 & 2031 (%)

Figure N0.42 GE Healthcare: Financials

Figure N0.43 Hitachi, Ltd: Financials

Figure N0.44 Koninklijke Philips N.V.: Financials

Figure N0.45 Siemens AG : Financials

Figure N0.46 SonoCiné Inc: Financials

Figure N0.47 Qview Medical : Financials

Figure N0.48 Koios Medical : Financials

Figure N0.49 Volpara Solutions Limited : Financials

Figure N0.50 Delphinus Medical Technologies, Inc.: Financials

Figure N0.51 Nova Medical Inc: Financials

글로벌 자동 유방 초음파 시스템(ABUS) 시장 – 2023-2030

Global Automated Breast Ultrasound Systems (ABUS) Market - 2023-2030